A Phase 1, Randomized, Placebo‐Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Subcutaneous Tezepelumab in Healthy Japanese Men

Tezepelumab, a human immunoglobulin G2 monoclonal antibody against thymic stromal lymphopoietin, is currently under clinical development for the treatment of severe, uncontrolled asthma. This phase 1, randomized, placebo‐controlled, single‐ascending‐dose study assessed the safety, tolerability, phar...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakamoto, Kei, Matsuki, Shunji, Irie, Shin, Uchida, Naoki, Hayashi, Nobuya, Horiuchi, Masato, Ren, Song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586988/
https://www.ncbi.nlm.nih.gov/pubmed/31960624
http://dx.doi.org/10.1002/cpdd.775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586988/
https://www.ncbi.nlm.nih.gov/pubmed/31960624
http://dx.doi.org/10.1002/cpdd.775

Ejemplares similares